Silicon Valley startups are pushing the boundaries of reproductive genetics, hoping to prevent diseases as well as improve chances for a high IQ ...

After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its remaining strategic commitment by reupping a pact with AI drug designer Nabla Bio.

Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In a recent study, his group and ...

The Druid AI platform offers a suite of agents to support the building of enterprise agents, including a conversational ...

Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In “Cardiovascular Research,” ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. As pharma companies and ...

Holtznagel has shared loved-up personal photographs with Joshua Clapp, himself a former model who is more comfortable behind the scenes these days as the man behind interior design and construction ...

Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing deals featuring Chinese biotechs. Fierce's deep dive into the dispute between Novo Nordisk and KBP Biosciences ...

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in select other countries with participating pharmaceutical manufacturers. Under ...

A drug addict stole more than £500-worth of designer goods when he targeted the same shop twice in three days. Mark Mann, who has 69 offences for theft alone on his appalling record, helped himself to ...